Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Anixa Biosciences Inc (NASDAQ:ANIX) Chief Executive Officer Amit Kumar reported purchasing 5,000 shares of the company’s common stock on July 11, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were bought at a price of $3.15, totaling $15,750. The purchase comes as the $101 million market cap company maintains a strong financial position with a current ratio of 8.89 and more cash than debt on its balance sheet. InvestingPro data shows the stock has surged ~47% over the past six months, with analysts setting price targets between $7-$10.
Following the transaction, Kumar directly owns 574,925 shares of Anixa Biosciences Inc. Want deeper insights into insider trading patterns and 8 additional key InvestingPro Tips for ANIX? Unlock comprehensive analysis with InvestingPro.
In other recent news, Anixa Biosciences announced that the United States Patent and Trademark Office will issue a new patent covering its ovarian cancer vaccine technology on July 15. This patent strengthens protection for the vaccine, developed in collaboration with Cleveland Clinic and the National Cancer Institute, focusing on high-risk populations. In another development, Anixa has dosed the first patient in the fourth cohort of its Phase 1 clinical trial for a CAR-T therapy targeting recurrent ovarian cancer. This trial, conducted with Moffitt Cancer Center, aims to evaluate safety and efficacy, with promising signs observed at early dosage levels.
Additionally, H.C. Wainwright has maintained its Buy rating and a $7.00 price target for Anixa Biosciences. This follows the completion of enrollment in a Phase 1 trial for the company’s breast cancer vaccine, developed with Cleveland Clinic and funded by the U.S. Department of Defense. Preliminary data from this trial indicate that over 70% of patients demonstrated an immune response. Anixa plans to submit a final study report to the Department of Defense and a clinical study report to the FDA after final patient visits in August 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.